Last 7 days
-8.2%
Last 30 days
-4.6%
Last 90 days
-16.2%
Trailing 12 Months
-11.3%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-09-14 | GRAHAM RICHARD A | sold | -24,547 | 9.89 | -2,482 | svp, research & development |
2023-08-22 | Farnum Rhonda | sold | -17,112 | 9.47 | -1,807 | svp, comm & medical affairs |
2023-08-20 | Winningham Rick E | sold (taxes) | -153,299 | 9.7 | -15,804 | chief executive officer |
2023-08-20 | Sawaf Aziz | sold (taxes) | -69,005 | 9.7 | -7,114 | svp & chief financial officer |
2023-08-20 | GRAHAM RICHARD A | sold (taxes) | -101,472 | 9.7 | -10,461 | svp, research & development |
2023-08-20 | Grimaud Brett A. | sold (taxes) | -86,446 | 9.7 | -8,912 | svp, gen counsel and secretary |
2023-08-20 | Farnum Rhonda | sold (taxes) | -101,462 | 9.7 | -10,460 | svp, comm & medical affairs |
2023-08-11 | GRAHAM RICHARD A | sold | -23,196 | 9.99 | -2,322 | svp, research & development |
2023-07-14 | GRAHAM RICHARD A | sold | -22,848 | 9.84 | -2,322 | svp, research & development |
2023-06-14 | GRAHAM RICHARD A | sold | -24,822 | 10.69 | -2,322 | svp, research & development |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-08-21 | OSAIC HOLDINGS, INC. | unchanged | - | -69.00 | 1,428 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -5.32 | -72,150 | 672,854 | -% |
2023-08-16 | Nuveen Asset Management, LLC | added | 1.82 | -48,645 | 1,628,360 | -% |
2023-08-15 | GOLDMAN SACHS GROUP INC | added | 1.24 | -125,033 | 3,525,200 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | added | 81.07 | 106,366 | 252,623 | -% |
2023-08-15 | ALLIANCEBERNSTEIN L.P. | unchanged | - | -38,868 | 804,557 | -% |
2023-08-14 | Bleakley Financial Group, LLC | new | - | 245,295 | 245,295 | 0.01% |
2023-08-14 | CANTOR FITZGERALD, L. P. | unchanged | - | -10,000 | 207,000 | -% |
2023-08-14 | Graham Capital Management, L.P. | reduced | -18.23 | -42,789 | 151,751 | -% |
2023-08-14 | PDT Partners, LLC | reduced | -0.25 | -43,282 | 850,335 | 0.12% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Aug 14, 2023 | weiss asset management lp | 14.% | 7,457,060 | SC 13D/A | |
Jul 10, 2023 | baupost group llc/ma | 12.84% | 7,419,226 | SC 13G/A | |
Apr 12, 2023 | weiss asset management lp | 11.% | 7,457,060 | SC 13D | |
Feb 14, 2023 | madison avenue partners, lp | 10.4% | 7,012,226 | SC 13G/A | |
Feb 14, 2023 | orbimed advisors llc | 0% | 0 | SC 13G/A | |
Feb 13, 2023 | baupost group llc/ma | 16.95% | 11,419,226 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 8.25% | 5,558,839 | SC 13G/A | |
Jan 30, 2023 | barclays plc | 5.00% | 3,371,298 | SC 13G | |
Sep 20, 2022 | gsk plc | 0.0% | 0 | SC 13D/A | |
Jun 16, 2022 | weiss asset management lp | 8.09% | 6,157,360 | SC 13G |
Date Filed | Form Type | Document | |
---|---|---|---|
Sep 18, 2023 | 4 | Insider Trading | |
Sep 14, 2023 | 144 | Notice of Insider Sale Intent | |
Sep 12, 2023 | 8-K | Current Report | |
Aug 24, 2023 | 4 | Insider Trading | |
Aug 22, 2023 | 4 | Insider Trading | |
Aug 22, 2023 | 4 | Insider Trading | |
Aug 22, 2023 | 4 | Insider Trading | |
Aug 22, 2023 | 4 | Insider Trading | |
Aug 22, 2023 | 4 | Insider Trading | |
Aug 15, 2023 | 4 | Insider Trading |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
LLY | 512.5B | 29.5B | 3.56% | 89.32% | 78.88 | 17.36 | 1.53% | 14.16% |
JNJ | 423.3B | 97.8B | -2.65% | 0.10% | 32.43 | 4.33 | 2.29% | -28.92% |
MRK | 272.8B | 58.3B | -2.13% | 26.48% | 17.88 | 4.63 | 2.00% | -81.24% |
PFE | 189.8B | 77.9B | -9.16% | -24.26% | 8.84 | 2.44 | -23.04% | -26.74% |
BMY | 150.1B | 45.2B | -5.06% | -15.06% | 23.72 | 3.25 | -4.15% | 20.34% |
MID-CAP | ||||||||
PRGO | 4.5B | 4.6B | -11.49% | -16.32% | -66.69 | 0.98 | 6.60% | 42.04% |
SMALL-CAP | ||||||||
PRVB | 2.2B | 12.9M | 4.30% | 396.62% | -19.28 | 169.83 | 824.37% | 0.76% |
TLRY | 1.9B | 627.1M | -7.75% | -1.79% | -1.34 | 3.1 | -0.20% | -204.67% |
PCRX | 1.6B | 669.2M | -8.68% | -37.33% | -350.4 | 2.39 | 8.94% | -111.64% |
CRON | 830.8M | 109.5M | 21.79% | -27.57% | -5.79 | 7.59 | -2.66% | -32.13% |
TBPH | 486.5M | 51.3M | -4.63% | -11.35% | 0.56 | 9.49 | -2.14% | 955.88% |
CGC | 480.0M | 453.3M | 110.37% | -71.69% | -0.39 | 1.06 | -16.04% | 55.90% |
NGM | 100.9M | 29.7M | -47.86% | -91.50% | -0.59 | 3.39 | -56.77% | -25.62% |
-17.7%
-20.8%
-20.2%
87.3%
81.9%
53.1%
Y-axis is the maximum loss one would have experienced if Theravance Biopharma was unfortunately bought at previous high price.
Income Statement (Last 12 Months) | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Revenue | 5.6% | 51,266,000 | 48,567,000 | 51,346,000 | 51,643,000 | 52,386,000 | 54,250,000 | 55,311,000 | 59,095,000 | 64,158,000 | 66,252,000 | 71,857,000 | 82,626,000 | 76,796,000 | 87,938,000 | 73,414,000 | 59,652,000 | 60,063,000 | 57,389,000 | 60,370,000 | 49,148,000 | 40,585,000 |
Operating Expenses | -3.5% | 118,877,000 | 123,156,000 | 138,246,000 | 177,278,000 | 222,492,000 | 265,365,000 | 313,095,000 | 337,202,000 | 365,265,000 | 375,425,000 | 369,614,000 | 374,465,000 | 357,221,000 | 338,663,000 | 325,329,000 | 303,616,000 | 301,276,000 | 304,830,000 | 299,121,000 | 304,454,000 | 290,438,000 |
S&GA Expenses | 4.5% | 70,706,000 | 67,650,000 | 67,073,000 | 71,857,000 | 76,879,000 | 86,588,000 | 99,296,000 | 107,705,000 | 113,907,000 | 112,756,000 | 108,531,000 | 111,652,000 | 109,773,000 | 107,220,000 | 106,081,000 | 98,492,000 | 94,760,000 | 97,540,000 | 97,058,000 | 101,124,000 | 100,178,000 |
R&D Expenses | -10.2% | 48,565,000 | 54,064,000 | 63,392,000 | 79,270,000 | 113,142,000 | 149,311,000 | 193,657,000 | 227,596,000 | 251,228,000 | 262,539,000 | 260,953,000 | 262,813,000 | 247,448,000 | 231,443,000 | 219,248,000 | 204,492,000 | 205,179,000 | 207,401,000 | 201,348,000 | 200,131,000 | 186,781,000 |
EBITDA | 100.0% | - | -46,432,000 | -86,446,000 | 23,601,000 | -6,096,000 | -98,876,000 | -152,688,000 | -187,718,000 | -226,122,000 | -233,091,000 | -238,477,000 | -240,446,000 | -234,384,000 | -214,663,000 | -206,340,000 | - | - | - | - | - | - |
EBITDA Margin | 100.0% | - | -0.96 | -1.68 | 0.46 | -0.12 | -1.82 | -2.76 | -3.18 | -3.52 | -3.52 | -3.32 | -2.91 | -3.05 | -2.44 | -2.81 | - | - | - | - | - | - |
Interest Expenses | -32.8% | 3,213,000 | 4,782,000 | 6,369,000 | 7,956,000 | 8,547,000 | 18,022,000 | 8,547,000 | 1,263,000 | 10,700,000 | 10,479,000 | 8,547,000 | 40,940,000 | 37,435,000 | 33,945,000 | 31,862,000 | 27,898,000 | 21,967,000 | 16,203,000 | 10,482,000 | 8,548,000 | 8,547,000 |
Earnings Before Taxes | 11.4% | -66,952,000 | -75,563,000 | -92,815,000 | -136,522,000 | -176,416,000 | -206,243,000 | -265,222,000 | -272,033,000 | -289,666,000 | -299,889,000 | -303,343,000 | -284,861,000 | -275,294,000 | -252,083,000 | -241,677,000 | -229,562,000 | -225,671,000 | -233,642,000 | -226,085,000 | -252,576,000 | -258,493,000 |
EBT Margin | 100.0% | - | -1.26 | -1.81 | -0.81 | -1.56 | -2.68 | -3.61 | -3.97 | -4.25 | -4.27 | -3.99 | -3.45 | -3.58 | -2.87 | -3.29 | - | - | - | - | - | - |
Net Income | -0.9% | 868,536,000 | 875,990,000 | 872,132,000 | 850,460,000 | -101,479,000 | -145,693,000 | -199,426,000 | -225,826,000 | -264,161,000 | -274,643,000 | -278,017,000 | -285,189,000 | -269,977,000 | -246,928,000 | -236,455,000 | -221,035,000 | -222,037,000 | -223,017,000 | -215,524,000 | -252,260,000 | -259,704,000 |
Net Income Margin | -100.0% | - | 18.04 | 16.99 | 16.47 | -1.94 | -2.69 | -3.61 | -3.82 | -4.12 | -4.15 | -3.87 | -3.45 | -3.52 | -2.81 | -3.22 | - | - | - | - | - | - |
Free Cashflow | 100.0% | - | -172,143,000 | -186,991,000 | -105,370,000 | -128,679,000 | -164,062,000 | -207,858,000 | -230,349,000 | -261,934,000 | -267,302,000 | -252,538,000 | -251,965,000 | -219,556,000 | -214,240,000 | -240,332,000 | - | - | - | - | - | - |
Balance Sheet | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Assets | -17.1% | 447 | 539 | 607 | 763 | 361 | 355 | 375 | 403 | 429 | 375 | 469 | 512 | 564 | 605 | 409 | 445 | 492 | 531 | 560 | 371 | 421 |
Current Assets | -26.5% | 192 | 261 | 353 | 512 | 155 | 205 | 250 | 297 | 333 | 293 | 393 | 451 | 498 | 534 | 338 | 356 | 426 | 467 | 533 | 333 | 387 |
Cash Equivalents | -43.7% | 106 | 188 | 298 | 419 | 87.00 | 94.00 | 91.00 | 121 | 205 | 114 | 81.00 | 93.00 | 105 | 333 | 59.00 | 102 | 178 | 223 | 379 | 101 | 104 |
Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.00 | 18.00 |
Net PPE | -21.1% | 10.00 | 12.00 | 12.00 | 12.00 | 13.00 | 13.00 | 14.00 | 16.00 | 17.00 | 17.00 | 16.00 | 15.00 | 14.00 | 14.00 | 13.00 | 12.00 | 13.00 | 13.00 | 13.00 | 12.00 | 11.00 |
Current Liabilities | -6.3% | 25.00 | 26.00 | 29.00 | 142 | 33.00 | 44.00 | 59.00 | 66.00 | 67.00 | 86.00 | 124 | 104 | 107 | 98.00 | 112 | 109 | 110 | 114 | 99.00 | 102 | 93.00 |
Shareholder's Equity | -24.4% | 280 | 371 | 442 | 481 | -349 | -351 | -338 | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.00 |
Retained Earnings | -1.8% | -891 | -876 | -853 | -843 | -1,760 | -1,751 | -1,726 | -1,694 | -1,658 | -1,606 | -1,526 | -1,468 | -1,394 | -1,331 | -1,248 | -1,182 | -1,124 | -1,084 | -1,012 | -961 | -902 |
Additional Paid-In Capital | -6.0% | 1,172 | 1,247 | 1,296 | 1,324 | 1,410 | 1,401 | 1,387 | 1,370 | 1,358 | 1,233 | 1,223 | 1,207 | 1,192 | 1,173 | 1,025 | 1,000 | 987 | 972 | 961 | 949 | 937 |
Shares Outstanding | -11.3% | 54.00 | 61.00 | 65.00 | 67.00 | 76.00 | 75.00 | 74.00 | 74.00 | 66.00 | 64.00 | 64.00 | 63.00 | 61.00 | 59.00 | 57.00 | 56.00 | 55.00 | 55.00 | 54.00 | 54.00 | 54.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Cashflow From Operations | 1.3% | -169 | -172 | -186 | -105 | -128 | -164 | -207 | -230 | -261 | -265 | -250 | -249 | -217 | -212 | -238 | -226 | -230 | -243 | -112 | -104 | -118 |
Share Based Compensation | -10.7% | 29.00 | 32.00 | 40.00 | 50.00 | 56.00 | 61.00 | 62.00 | 61.00 | 62.00 | 64.00 | 63.00 | 71.00 | 69.00 | 64.00 | 60.00 | 48.00 | 47.00 | 50.00 | 51.00 | 57.00 | 56.00 |
Cashflow From Investing | 0.3% | 1,083 | 1,079 | 1,154 | 1,126 | 14.00 | 43.00 | 124 | 166 | 268 | 56.00 | 11.00 | -27.59 | -117 | 58.00 | -83.05 | 2.00 | 73.00 | 116 | 177 | 119 | 87.00 |
Cashflow From Financing | -9.9% | -894 | -813 | -758 | -723 | -3.44 | 102 | 92.00 | 92.00 | 94.00 | -9.63 | 263 | 261 | 262 | 264 | 1.00 | 232 | 232 | 225 | 225 | -3.77 | -4.24 |
Buy Backs | 7.8% | 265 | 246 | 129 | 376 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||||
---|---|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |||
Revenue: | ||||||
Total revenue | $ 13,749 | $ 11,050 | $ 24,166 | $ 24,246 | ||
Expenses: | ||||||
Research and development (1) | [1] | 9,425 | 14,924 | 23,997 | 38,177 | |
Selling, general and administrative (1) | [1] | 19,278 | 16,222 | 38,461 | 34,064 | |
Restructuring and related expenses (1) | [1] | 1,169 | 3,005 | 2,743 | 12,329 | |
Total expenses | 29,872 | 34,151 | 65,201 | 84,570 | ||
Loss from operations | (16,123) | (23,101) | (41,035) | (60,324) | ||
Interest expense | (568) | (2,137) | (1,118) | (4,274) | ||
Interest income and other income (expense), net | 2,504 | 2,440 | 5,483 | 2,065 | ||
Loss from continuing operations before income taxes | (14,187) | (22,798) | (36,670) | (62,533) | ||
Provision for income tax (expense) benefit | (1,458) | 5 | (1,063) | (519) | ||
Net loss from continuing operations | (15,645) | (22,793) | (37,733) | (63,052) | ||
Income from discontinued operations before income taxes | 14,602 | 28,915 | ||||
Provision for income tax expense | ||||||
Net income from discontinued operations | 14,602 | 28,915 | ||||
Net loss | (15,645) | (8,191) | (37,733) | (34,137) | ||
Net unrealized loss on available-for-sale investments | (337) | (17) | (271) | (45) | ||
Total comprehensive loss | $ (15,982) | $ (8,208) | $ (38,004) | $ (34,182) | ||
Net income (loss) per share: | ||||||
Continuing operations - basic | $ (0.28) | $ (0.30) | $ (0.63) | $ (0.83) | ||
Continuing operations - diluted | (0.28) | (0.30) | (0.63) | (0.83) | ||
Discontinued operations - basic | 0.19 | 0.38 | ||||
Discontinued operations - diluted | 0.19 | 0.38 | ||||
Net loss - basic | (0.28) | (0.11) | (0.63) | (0.45) | ||
Net loss - diluted | $ (0.28) | $ (0.11) | $ (0.63) | $ (0.45) | ||
Shares used to compute net income (loss) per share - basic | 56,682 | 76,270 | 59,791 | 75,761 | ||
Shares used to compute net income (loss) per share - diluted | 56,682 | 76,270 | 59,791 | 75,761 | ||
Total share-based compensation expense | $ 6,264 | $ 9,709 | $ 13,285 | $ 24,254 | ||
Research and development | ||||||
Expenses: | ||||||
Restructuring and related expenses (1) | 1,200 | 1,000 | 2,700 | 5,700 | ||
Net income (loss) per share: | ||||||
Total share-based compensation expense | 1,855 | 2,909 | 4,296 | 7,439 | ||
Selling, general and administrative | ||||||
Expenses: | ||||||
Restructuring and related expenses (1) | 2,000 | 6,600 | ||||
Net income (loss) per share: | ||||||
Total share-based compensation expense | 4,409 | 5,030 | 8,632 | 10,528 | ||
Restructuring and related expenses | ||||||
Net income (loss) per share: | ||||||
Total share-based compensation expense | 1,770 | 357 | 6,287 | |||
Viatris collaboration agreement | ||||||
Revenue: | ||||||
Total revenue | 13,743 | 10,878 | 24,154 | 21,565 | ||
Collaboration revenue | ||||||
Revenue: | ||||||
Total revenue | $ 6 | $ 172 | $ 12 | 181 | ||
Licensing revenue | ||||||
Revenue: | ||||||
Total revenue | $ 2,500 | |||||
|
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 105,596 | $ 298,172 |
Short-term marketable securities | 61,855 | 29,312 |
Receivables from collaborative arrangements | 15,796 | 16,785 |
Prepaid clinical and development services | 979 | 1,513 |
Other prepaid and current assets | 7,777 | 7,682 |
Total current assets | 192,003 | 353,464 |
Property and equipment, net | 9,553 | 11,875 |
Operating lease assets | 38,453 | 40,126 |
Future contingent milestone and royalty assets | 194,200 | 194,200 |
Restricted cash | 836 | 836 |
Other assets | 11,585 | 6,899 |
Total assets | 446,630 | 607,400 |
Current liabilities: | ||
Accounts payable | 1,569 | 1,554 |
Accrued personnel-related expenses | 5,371 | 10,314 |
Accrued clinical and development expenses | 4,006 | 4,932 |
Accrued general and administrative expenses | 2,874 | 4,020 |
Operating lease liabilities | 9,160 | 6,753 |
Deferred revenue | 24 | 24 |
Other accrued liabilities | 1,542 | 1,118 |
Total current liabilities | 24,546 | 28,715 |
Long-term operating lease liabilities | 42,521 | 45,407 |
Future royalty payment contingency | 26,556 | 25,438 |
Long-term deferred revenue | 181 | 192 |
Unrecognized tax benefits | 64,987 | 64,191 |
Other long-term liabilities | 7,678 | 1,657 |
Commitments and contingencies | ||
Shareholders' Equity | ||
Preferred shares, $0.00001 par value: 230 shares authorized, no shares issued or outstanding | ||
Ordinary shares, $0.00001 par value: 200,000 shares authorized; 53,694 and 65,227 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | 1 | 1 |
Additional paid-in capital | 1,172,090 | 1,295,725 |
Accumulated other comprehensive loss | (286) | (15) |
Accumulated deficit | (891,644) | (853,911) |
Total shareholders' equity | 280,161 | 441,800 |
Total liabilities and shareholders' equity | $ 446,630 | $ 607,400 |